Mytos GTM brain

category

market profile

• text: Manual manufacturing constrains the scaling and cost of regenerative therapies; Mytos offers automation and contract manufacturing as alternatives.
• text: Its 2025 CDMO launch targets scalable manufacturing of stem-cell derived therapies, alongside its existing platform offering.

personas

• title: Chief technology officer at a cell therapy developer
  pains:

  • Translate a manual cell culture process into a repeatable automated workflow
  • Expand capacity for late-stage trials without multiplying cleanroom space and operators
• title: Head of manufacturing or MSAT
  pains:

  • Prove process transfer and quality before committing manufacturing capacity
  • Reduce labor and cost per batch while retaining a viable path to commercial supply
• title: Biotech CEO or business development leader
  pains:

  • Secure manufacturing capacity as clinical programs progress
  • Balance automation investment against uncertain commercial demand

icp

• text: Biotechnology and pharmaceutical companies developing stem-cell derived regenerative therapies, especially those approaching later-stage trials or commercialization.
• text: Teams producing specialized human cells or tissues, including neurology, vision, hearing and bone repair programs.
• text: US and UK therapy developers with manual cell culture processes and a need for scalable manufacturing; size is less decisive than program maturity.

message pillars

• text: Remove manual production as the scaling bottleneck.
• text: Fit more batches into existing cleanroom capacity.
• text: Demonstrate process fit and return before scaling.

objections

• objection: Our cell process is too specialized to automate.
  response: Scope a proof-of-value study to translate the specific process and evaluate technical fit before scaling.
• objection: Automated manufacturing may not support our clinical scale-up.
  response: Discuss the Aspen Neuroscience collaboration and request evidence relevant to the buyer's own process and stage.
• objection: The economics may not justify a switch from manual manufacturing.
  response: Use a tailored study to measure process-specific labor, capacity and cost rather than assume advertised results apply.

competitors

• name: Cellares
  why: Automated cell therapy manufacturing platform and capacity provider.
• name: Ori Biotech
  why: Automated cell therapy manufacturing platform competes for process development and scale-up.
• name: Lonza
  why: Established cell and gene therapy CDMO competing for outsourced manufacturing programs.

influencers

• name: Ignacio Willats
  url: https://www.linkedin.com/in/ignaciowillats
  why: Co-founder and commercial leader with a direct perspective on customer manufacturing needs.

keywords

• stem cell manufacturing automation
• iPSC cell therapy CDMO
• automated cell culture manufacturing
• regenerative medicine scale up
• cell therapy manufacturing cost
• clinical cell therapy manufacturing

voice

• mission-driven
• quantitative
• technical but accessible

signals

• text: A stem-cell therapy developer announces Phase 2 or Phase 3 plans and needs to expand cell supply.
• text: A company hires MSAT or cell manufacturing staff while building out manual production capacity.

stack

• iDEM automated cell manufacturing technology

hiring

• Business Development Manager, United States
• Principal Scientist (PD/MSAT), London
• Quality (QA) Lead - CDMO, London and Stevenage

pricing

motion

channels

• website
• LinkedIn
• industry partnerships

confidence

Founders

• name: Ali Afshar
  title: Founder/CEO
  role: CEO
  bio: CEO and Co-Founder of Mytos. I'm a mixture between a scientist and an engineer, having solved challenges both using physics/chemistry, as well as through building hardware and software. I aspire to operate at the interface of science and engineering, where low level science translates into meaningful products.
• name: Ignacio Willats
  title: Founder
  role: Founder